Literature DB >> 3281884

Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis.

A B Lumsden1, J M Henderson, M H Kutner.   

Abstract

Endotoxin concentrations were measured in the portal, hepatic and peripheral venous blood of two groups of patients with cirrhosis using a limulus-based chromogenic assay. The high sensitivity of chromogenic detection allowed measurement of endotoxin as low as 10 to 15 pg per ml, an order of magnitude greater than previously possible by gelation studies. Group 1 consisted of 56 patients with cirrhosis undergoing angiographic evaluation. In this group, there was wide variability in hepatic venous concentration [73 +/- 110 pg per ml (mean +/- S.D.)] and peripheral venous concentration [31 +/- 58 pg per ml]. However, paired t test showed peripheral venous concentration was significantly (p less than 0.001) lower than hepatic venous concentration. Neither hepatic or peripheral venous endotoxin levels correlated significantly with a variety of clinical, biochemical or radiological parameters. Group 2 consisted of 21 patients with cirrhosis undergoing shunt surgery. Endotoxin levels again showed a wide range, with portal venous concentration (142 +/- 167 pg per ml) and simultaneous peripheral venous concentration (82 +/- 150 pg per ml). Paired t test in this group showed a significant (p less than 0.001) portal to peripheral venous gradient. This study showed the feasibility of measuring endotoxin in plasma to low concentrations by a chromogenic assay technique. It supports the concept of relatively high levels of endotoxin in the portal circulation. In the presence of liver disease, systemic endotoxemia occurs, which is augmented by stressful situations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281884     DOI: 10.1002/hep.1840080207

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  92 in total

1.  E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide.

Authors:  T Kawata; J R Bristol; D P Rossignol; J R Rose; S Kobayashi; H Yokohama; A Ishibashi; W J Christ; K Katayama; I Yamatsu; Y Kishi
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

2.  Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility.

Authors:  R Wiest; S Das; G Cadelina; G Garcia-Tsao; S Milstien; R J Groszmann
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 3.  The hepatorenal syndrome.

Authors:  L Dagher; K Moore
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 4.  Nitric oxide in patients with cirrhosis and bacterial infections.

Authors:  José Such; Rubén Francés; Miguel Pérez-Mateo
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

Review 5.  Why some organ allografts are tolerated better than others: new insights for an old question.

Authors:  Travis D Hull; Gilles Benichou; Joren C Madsen
Journal:  Curr Opin Organ Transplant       Date:  2019-02       Impact factor: 2.640

6.  Role of serotonin in development of esophageal and gastric fundal varices.

Authors:  Jelena S Rudić; Dorđe M Culafić; Duško S Mirković; Rada S Ješić; Miodrag N Krstić
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

7.  Hepatic Stellate Cells Directly Inhibit B Cells via Programmed Death-Ligand 1.

Authors:  Yan Li; Lina Lu; Shiguang Qian; John J Fung; Feng Lin
Journal:  J Immunol       Date:  2016-01-11       Impact factor: 5.422

Review 8.  Renal dysfunction associated with liver transplantation.

Authors:  R M Jindal; I Popescu
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401

Review 9.  Immune surveillance by the liver.

Authors:  Craig N Jenne; Paul Kubes
Journal:  Nat Immunol       Date:  2013-09-18       Impact factor: 25.606

10.  Human immunodeficiency virus-related microbial translocation and progression of hepatitis C.

Authors:  Ashwin Balagopal; Frances H Philp; Jacquie Astemborski; Timothy M Block; Anand Mehta; Ronald Long; Gregory D Kirk; Shruti H Mehta; Andrea L Cox; David L Thomas; Stuart C Ray
Journal:  Gastroenterology       Date:  2008-03-29       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.